Spectral AI (NASDAQ:MDAI) & Inogen (NASDAQ:INGN) Financial Contrast

Spectral AI (NASDAQ:MDAI) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Volatility and Risk

Spectral AI has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Inogen has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.

Insider & Institutional Ownership

67.1% of Spectral AI shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 30.7% of Spectral AI shares are held by insiders. Comparatively, 1.5% of Inogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Spectral AI and Inogen”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$29.58 million	1.66	-$15.31 million	($0.69)	-2.32
Inogen	$335.70 million	0.57	-$35.89 million	($1.01)	-7.02

Spectral AI has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Spectral AI and Inogen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1	0	2	0	2.33
Inogen	1	1	1	0	2.00

Spectral AI presently has a consensus target price of $3.25, indicating a potential upside of 103.13%. Inogen has a consensus target price of $11.00, indicating a potential upside of 55.15%. Given Spectral AI’s stronger consensus rating and higher possible upside, analysts clearly believe Spectral AI is more favorable than Inogen.

Profitability

This table compares Spectral AI and Inogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-70.64%	N/A	-27.16%
Inogen	-7.31%	-13.21%	-8.30%

Summary

Spectral AI beats Inogen on 9 of the 14 factors compared between the two stocks.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.